A detailed history of Bell Investment Advisors, Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Bell Investment Advisors, Inc holds 260 shares of FATE stock, worth $345. This represents 0.0% of its overall portfolio holdings.

Number of Shares
260
Previous 260 -0.0%
Holding current value
$345
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$1.65 - $3.94 $429 - $1,024
260 New
260 $0
Q3 2022

Nov 09, 2022

SELL
$21.04 - $36.06 $252 - $432
-12 Reduced 14.81%
69 $2,000
Q2 2022

Aug 12, 2022

BUY
$17.78 - $42.39 $835 - $1,992
47 Added 138.24%
81 $2,000
Q4 2021

Feb 14, 2022

BUY
$47.84 - $64.34 $287 - $386
6 Added 21.43%
34 $2,000
Q3 2021

Nov 12, 2021

BUY
$59.27 - $95.73 $1,659 - $2,680
28 New
28 $2,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $129M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Bell Investment Advisors, Inc Portfolio

Follow Bell Investment Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bell Investment Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bell Investment Advisors, Inc with notifications on news.